Early Canadian approval of IVIGPL mentioned that only 6 months of monitoring is required as part of the trials compared 12 months under the FDA process. This means that PLI can submit a BLA for IVIG in Canada 6 months earlier than in the USA. It will be important to clarify the new timelines and when IVIG will be commercialised in Canada. I am starting to think that this could happen in Q4 2018. I believe that the Canadian market is more than large enough to handle the amount of IVIG that PLI can produce. The marketing is also easier as CBS and hemaQuebec purchase/distribute all IVI requirements in Canada.